No therapy has shown to increase overall survival (OS) of patients with advanced BRAFV600 wild-type melanoma (50% of melanoma patients) who progress beyond treatment with programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint inhibitors (ICI). The gene discussed is CTLA4; the disease is melanoma.